Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase.

AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...